Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

WORK Medical Technology (WOK) Common Equity (2023 - 2025)

Historic Common Equity for WORK Medical Technology (WOK) over the last 3 years, with Q3 2025 value amounting to $21.2 million.

  • WORK Medical Technology's Common Equity rose 3170.03% to $21.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $21.2 million, marking a year-over-year increase of 3170.03%. This contributed to the annual value of $21.2 million for FY2025, which is 3170.03% up from last year.
  • Per WORK Medical Technology's latest filing, its Common Equity stood at $21.2 million for Q3 2025, which was up 3170.03% from $12.9 million recorded in Q1 2025.
  • In the past 5 years, WORK Medical Technology's Common Equity ranged from a high of $21.2 million in Q3 2025 and a low of $11.0 million during Q3 2023
  • Its 3-year average for Common Equity is $15.3 million, with a median of $14.5 million in 2024.
  • Its Common Equity has fluctuated over the past 5 years, first surged by 4628.16% in 2024, then surged by 3170.03% in 2025.
  • WORK Medical Technology's Common Equity (Quarter) stood at $11.0 million in 2023, then soared by 46.28% to $16.1 million in 2024, then soared by 31.7% to $21.2 million in 2025.
  • Its Common Equity stands at $21.2 million for Q3 2025, versus $12.9 million for Q1 2025 and $16.1 million for Q3 2024.